Kidney Pathology and Outcomes in ANCA-Associated Vasculitis: Retrospective Analysis of 85 Patients
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Main Disease Characteristics
3.2. Kidney Survival Analysis in the Main Study Group
3.3. Kidney Survival Analysis in the Anti-PR3-ANCA and Anti-MPO-ANCA Subgroups
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Jennette, J.C.; Falk, R.J. Small-Vessel Vasculitis. N. Engl. J. Med. 1997, 337, 1512–1523. [Google Scholar] [CrossRef]
- Flossmann, O.; Berden, A.; de Groot, K.; Hagen, C.; Harper, L.; Heijl, C.; Höglund, P.; Jayne, D.; Luqmani, R.; Mahr, A.; et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 2011, 70, 488–494. [Google Scholar] [CrossRef]
- Mukhtyar, C.; Flossmann, O.; Hellmich, B.; Bacon, P.; Cid, M.; Cohen-Tervaert, J.W.; Gross, W.L.; Guillevin, L.; Jayne, D.; Mahr, A.; et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: A systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann. Rheum. Dis. 2008, 67, 1004–1010. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mukhtyar, C.; Guillevin, L.; Cid, M.C.; Dasgupta, B.; De Groot, K.; Gross, W.; Hauser, T.; Hellmich, B.; Jayne, D.; Kallenberg, C.G.M.; et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 2008, 68, 310–317. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schirmer, J.H.; Wright, M.; Vonthein, R.; Herrmann, K.; Nölle, B.; Both, M.; Henes, F.O.; Arlt, A.; Gross, W.L.; Schinke, S.; et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology 2016, 55, 71–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rhee, R.L.; Hogan, S.L.; Poulton, C.J.; McGregor, J.A.G.; Landis, J.R.; Falk, R.J.; Merkel, P.A. Trends in Long-Term Outcomes Among Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Renal Disease. Arthritis Rheumatol. 2016, 68, 1711–1720. [Google Scholar] [CrossRef] [Green Version]
- Shi, J.; Shen, Q.; Chen, X.-M.; Du, X.-G. Clinical characteristics and outcomes in microscopic polyangiitis patients with renal involvement: A study of 124 Chinese patients. BMC Nephrol. 2019, 20, 339. [Google Scholar] [CrossRef] [Green Version]
- Durel, C.-A.; Sinico, R.A.; Teixeira, V.; Jayne, D.; Belenfant, X.; Marchand-Adam, S.; Pugnet, G.; Gaultier, J.; Le Gallou, T.; Titeca-Beauport, D.; et al. Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): A multicentric retrospective study of 63 biopsy-proven cases. Rheumatology 2021, 60, 359–365. [Google Scholar] [CrossRef]
- Jones, R.B.; Tervaert, J.W.C.; Hauser, T.; Luqmani, R.; Morgan, M.D.; Peh, C.A.; Savage, C.O.; Segelmark, M.; Tesar, V.; Van Paassen, P.; et al. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. N. Engl. J. Med. 2010, 363, 211–220. [Google Scholar] [CrossRef] [Green Version]
- Cornec, D.; Gall, E.C.-L.; Fervenza, E.C.-L.G.F.C.; Specks, D.C.U. ANCA-associated vasculitis—Clinical utility of using ANCA specificity to classify patients. Nat. Rev. Rheumatol. 2016, 12, 570–579. [Google Scholar] [CrossRef]
- Salmela, A.; Törnroth, T.; Poussa, T.; Ekstrand, A. Prognostic Factors for Survival and Relapse in ANCA-Associated Vasculitis with Renal Involvement: A Clinical Long-Term Follow-Up Study. Int. J. Nephrol. 2018, 2018, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oristrell, J.; Loureiro-Amigo, J.; Solans, R.; Valenzuela, M.P.; Monsálvez, V.; Segarra, A.; Amengual, M.J.; Marín, A.; Feijoo, C.; Tolosa, C. Relapse rate and renal prognosis in ANCA-associated vasculitis according to long-term ANCA patterns. Clin. Exp. Immunol. 2021, 203, 209–218. [Google Scholar] [CrossRef] [PubMed]
- Booth, A.D.; Almond, M.K.; Burns, A.; Ellis, P.; Gaskin, G.; Neild, G.H.; Plaisance, M.; Pusey, C.D.; Jayne, D.R. Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am. J. Kidney Dis. 2003, 41, 776–784. [Google Scholar] [CrossRef]
- Walsh, M.; Casian, A.; Floßmann, O.; Westman, K.; Höglund, P.; Pusey, C.; Jayne, D.R. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013, 84, 397–402. [Google Scholar] [CrossRef] [Green Version]
- Walsh, M.; Merkel, P.A.; Peh, C.A.; Szpirt, W.M.; Puéchal, X.; Fujimoto, S.; Hawley, C.M.; Khalidi, N.; Floßmann, O.; Wald, R.; et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N. Engl. J. Med. 2020, 382, 622–631. [Google Scholar] [CrossRef]
- Moura, M.C.; Irazabal, M.V.; Eirin, A.; Zand, L.; Sethi, S.; Borah, B.J.; Winters, J.L.; Moriarty, J.P.; Cartin-Ceba, R.; Berti, A.; et al. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis with Severe Renal Disease. J. Am. Soc. Nephrol. 2020, 31, 2688–2704. [Google Scholar] [CrossRef]
- Kronbichler, A.; Kerschbaum, J.; Gründlinger, G.; Leierer, J.; Mayer, G.; Rudnicki, M. Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. Nephrol. Dial. Transplant. 2015, 31, 930–936. [Google Scholar] [CrossRef] [PubMed]
- Bajema, I.M.; Hagen, E.C.; Hansen, B.E.; Hermans, J.; Noel, L.H.; Waldherr, R.; Ferrario, F.; Van Der Woude, F.J.; Bruijn, J.A. The renal histopathology in systemic vasculitis: An international survey study of inter- and intra-observer agreement. Nephrol. Dial. Transplant. 1996, 11, 1989–1995. [Google Scholar] [CrossRef]
- Bajema, I.M.; Hagen, E.; Van Der Woude, F.J.; Bruijn, J.A. Wegener’s granulomatosis: A meta-analysis of 349 literary case reports. J. Lab. Clin. Med. 1997, 129, 17–22. [Google Scholar] [CrossRef]
- Jennette, J.C.; Falk, R.J.; Bacon, P.A.; Basu, N.; Cid, M.C.; Ferrario, F.; Flores-Suarez, L.F.; Gross, W.L.; Guillevin, L.; Hagen, E.C.; et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013, 65, 1–11. [Google Scholar] [CrossRef]
- Abdulkader, R.; Lane, S.E.; Scott, D.G.I.; Watts, R.A. Classification of vasculitis: EMA classification using CHCC 2012 definitions. Ann. Rheum. Dis. 2013, 72, 1888. [Google Scholar] [CrossRef]
- Berden, A.E.; Ferrario, F.; Hagen, E.C.; Jayne, D.R.; Jennette, J.C.; Joh, K.; Neumann, I.; Noël, L.-H.; Pusey, C.D.; Waldherr, R.; et al. Histopathologic Classification of ANCA-Associated Glomerulonephritis. J. Am. Soc. Nephrol. 2010, 21, 1628–1636. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berden, A.E.; Jones, R.; Erasmus, D.D.; Walsh, M.; Noël, L.-H.; Ferrario, F.; Waldherr, R.; Bruijn, J.A.; Jayne, D.R.; Bajema, I.M.; et al. Tubular Lesions Predict Renal Outcome in Antineutrophil Cytoplasmic Antibody–Associated Glomerulonephritis after Rituximab Therapy. J. Am. Soc. Nephrol. 2011, 23, 313–321. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kristensen, T.; Gregersen, J.W.; Krag, S.R.; Ivarsen, P. The relation between histopathological classification and renal outcome, ANCA subtype and treatment regimens in ANCA-associated vasculitis. Clin. Exp. Rheumatol. 2016, 34 (Suppl. 97), 105–110. [Google Scholar]
- Moroni, G.; Binda, V.; Leoni, A.; Raffiotta, F.; Quaglini, S.; Banfi, G.; Messa, P. Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopatological classification schema and review of the literature. Clin. Exp. Rheumatol. 2015, 33, 56–63. [Google Scholar]
- Sethi, S.; D’Agati, V.D.; Nast, C.C.; Fogo, A.B.; De Vriese, A.; Markowitz, G.S.; Glassock, R.J.; Fervenza, F.C.; Seshan, S.V.; Rule, A.; et al. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int. 2017, 91, 787–789. [Google Scholar] [CrossRef] [PubMed]
- Berti, A.; Gall, E.C.-L.; Cornec, D.; Moura, M.C.; Matteson, E.L.; Crowson, C.S.; Ravindran, A.; Sethi, S.; Fervenza, F.C.; Specks, U. Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrol. Dial. Transplant. 2019, 34, 1508–1517. [Google Scholar] [CrossRef]
- Brix, S.R.; Noriega, M.; Tennstedt, P.; Vettorazzi, E.; Busch, M.; Nitschke, M.; Jabs, W.J.; Özcan, F.; Wendt, R.; Hausberg, M.; et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018, 94, 1177–1188. [Google Scholar] [CrossRef]
- Hauer, H.A.; Bajema, I.M.; van Houwelingen, H.C.; Ferrario, F.; Noël, L.-H.; Waldherr, R.; Jayne, D.R.; Rasmussen, N.; Bruijn, J.A.; Hagen, E.C. Determinants of outcome in ANCA-associated glomerulonephritis: A prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002, 62, 1732–1742. [Google Scholar] [CrossRef] [Green Version]
- Hilhorst, M.; Wilde, B.; Vriesman, P.V.B.; Van Paassen, P.; Tervaert, J.W.C. Estimating Renal Survival Using the ANCA-Associated GN Classification. J. Am. Soc. Nephrol. 2013, 24, 1371–1375. [Google Scholar] [CrossRef] [Green Version]
- Fries, J.F.; Hunder, G.G.; Bloch, D.A.; Michel, B.A.; Arend, W.P.; Calabrese, L.H.; Fauci, A.S.; Leavitt, R.Y.; Lie, J.T.; Lightfoot, R.W.; et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: Summary. Arthritis Rheum. 2010, 33, 1135–1136. [Google Scholar] [CrossRef]
- Mukhtyar, C.; Lee, R.; Brown, D.; Carruthers, D.; Dasgupta, B.; Dubey, S.; Flossmann, O.; Hall, C.; Hollywood, J.; Jayne, D.; et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann. Rheum. Dis. 2009, 68, 1827–1832. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lai, K.N.; Chan, L.Y.; Leung, J.C. Mechanisms of tubulointerstitial injury in IgA nephropathy. Kidney Int. 2005, 67, S110–S115. [Google Scholar] [CrossRef] [Green Version]
- Nasr, S.H.; Collins, A.B.; Alexander, M.P.; Schraith, D.F.; Hernandez, L.H.; Fidler, M.E.; Sethi, S.; Leung, N.; Fervenza, F.C.; Cornell, L.D. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int. 2016, 89, 897–908. [Google Scholar] [CrossRef] [Green Version]
- Mariani, L.H.; Martini, S.; Barisoni, L.; Canetta, P.; Troost, J.P.; Hodgin, J.B.; Palmer, M.; Rosenberg, A.; Lemley, K.V.; Chien, H.-P.; et al. Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies. Nephrol. Dial. Transplant. 2018, 33, 310–318. [Google Scholar] [CrossRef] [Green Version]
- Chen, Y.-X.; Xu, J.; Pan, X.-X.; Shen, P.-Y.; Li, X.; Ren, H.; Chen, X.-N.; Ni, L.-Y.; Zhang, W.; Chen, N. Histopathological Classification and Renal Outcome in Patients with Antineutrophil Cytoplasmic Antibodies-associated Renal Vasculitis: A Study of 186 Patients and Metaanalysis. J. Rheumatol. 2016, 44, 304–313. [Google Scholar] [CrossRef]
- De Joode, A.A.E.; Sanders, J.S.F.; Stegeman, C.A. Renal Survival in Proteinase 3 and Myeloperoxidase ANCA-Associated Systemic Vasculitis. Clin. J. Am. Soc. Nephrol. 2013, 8, 1709–1717. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Plafkin, C.; Zhong, W.; Singh, T. ANCA vasculitis presenting with acute interstitial nephritis without glomerular involvement. Clin. Nephrol. Case Stud. 2019, 7, 46–50. [Google Scholar] [CrossRef]
- Franssen, C.F.; Gans, R.O.; Arends, B.; Hageluken, C.; ter Wee, P.M.; Gerlag, P.G.; Hoorntje, S.J. Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease. Kidney Int. 1995, 47, 193–199. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wijngaarden, R.A.D.L.V.; Hauer, H.A.; Wolterbeek, R.; Jayne, D.R.; Gaskin, G.; Rasmussen, N.; Noël, L.-H.; Ferrario, F.; Waldherr, R.; Hagen, E.C.; et al. Clinical and Histologic Determinants of Renal Outcome in ANCA-Associated Vasculitis: A Prospective Analysis of 100 Patients with Severe Renal Involvement. J. Am. Soc. Nephrol. 2006, 17, 2264–2274. [Google Scholar] [CrossRef] [PubMed]
- Kronbichler, A.; Jayne, D.R. ANCA Renal Risk Score: Is prediction of end-stage renal disease at baseline possible? Kidney Int. 2018, 94, 1045–1047. [Google Scholar] [CrossRef] [PubMed]
Systemic Features | All Patients (85) | Anti-PR3-Positive (25) | Anti-MPO-Positive (42) | ANCA Screening Test-Positive (10) | Sero-Negative (8) |
---|---|---|---|---|---|
Lungs, N (%) | |||||
Interstitial lung damage | 22 (25.9) | 8 (32) | 3 (30.9) | 2 (20) | 0 (0) |
Infiltrates | 16 (18.8) | 3 (12) | 8 (19) | 4 (40) | 1 (12.5) |
Cavities | 3 (3.5) | 3 (12) | 0 (0) | 2 (20) | 0 (0) |
Nodular masses | 3 (3.5) | 2 (8) | 1 (2.4) | 0 | 1 (12.5) |
Asthma | 7 (8.2) | 2 (8) | 4 (9.5) | 1 (10) | 2 (25) |
Hemoptysis, pulmonary hemorrhage | 11 (12.9) | 3 (12) | 6 (14.3) | 1 (10) | 1 (12.5) |
Skin, N (%) | 22 (25.8) | 6 (24) | 16 (38.1) | 2 (20) | 1 (12.5) |
Joints, N (%) | 27 (31.7) | 11 (44) | 12 (28.6) | 2 (20) | 2 (25) |
Gastrointestinal, N (%) | 6 (7.0) | 2 (8) | 3 (7.1) | 1 (10) | 1 (12.5) |
Nervous system, N (%) | 12 (14.1) | 6 (24) | 5 (11.9) | 0 | 1 (12.5) |
ENT, N (%) | 38 (44.7) | 19 (76) | 16 (38.1) | 2 (20) | 4 (50) |
Eyes, N (%) | 13 (15.3) | 8 (32) | 4 (9.5) | 0 (0) | 1 (12.5) |
BVAS v.3 at presentation | 15.0 (12.9; 19.8) | 15 (14; 20) | 15 (13; 20) | 14 (13; 18.5) | 18 (11; 20.5) |
Median serum creatinine at presentation, µmol/L | 257.0 (171.0; 528.5) | 203 (130; 311) | 139 (120; 347) | 250 (151.5; 576) | 100 (73; 308.5) |
Kidney pathology (Berden’s classification) | |||||
Focal, N (%) | 20 (23.5) | 3 (12) | 11 (26.2) | 3 (30) | 3 (37.5) |
Crescentic, N (%) | 22 (25.9) | 8 (32) | 9 (21.4) | 3 (30) | 2 (25) |
Mixed, N (%) | 18 (21.2) | 7 (28) | 9 (21.4) | 2 (20) | 0 (0) |
Sclerotic, N (%) | 24 (28.2) | 7 (28) | 12 (28.6) | 2 (20) | 3 (37.5) |
ARRS | |||||
Low, N (%) | 22 (25.9) | 7 (28) | 9 (21.4) | 2 (20) | 4 (25) |
Medium, N (%) | 42 (49.4) | 12 (48) | 21 (50) | 6 (60) | 3 (37.5) |
High, N (%) | 21 (24.7) | 6 (24) | 12 (28.6) | 2 (20) | 1 (12.5) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zakharova, E.; Zykova, A.; Makarova, T.; Leonova, E.; Stolyarevich, E. Kidney Pathology and Outcomes in ANCA-Associated Vasculitis: Retrospective Analysis of 85 Patients. Kidney Dial. 2021, 1, 61-73. https://doi.org/10.3390/kidneydial1010010
Zakharova E, Zykova A, Makarova T, Leonova E, Stolyarevich E. Kidney Pathology and Outcomes in ANCA-Associated Vasculitis: Retrospective Analysis of 85 Patients. Kidney and Dialysis. 2021; 1(1):61-73. https://doi.org/10.3390/kidneydial1010010
Chicago/Turabian StyleZakharova, Elena, Anastasiia Zykova, Tatyana Makarova, Eugenia Leonova, and Ekaterina Stolyarevich. 2021. "Kidney Pathology and Outcomes in ANCA-Associated Vasculitis: Retrospective Analysis of 85 Patients" Kidney and Dialysis 1, no. 1: 61-73. https://doi.org/10.3390/kidneydial1010010